+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07787156

Evaluating Remote Genetic and Multi-Cancer Early Detection Education to Improve Testing Access Among Black, Latinoa, and Medicaid-enrolled Adults at Risk for Pancreatic Cancer

Led by Brigham and Women's Hospital · Updated on 2026-10-22

80

Participants Needed

1

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a remote approach to support people at higher risk for pancreatic cancer, focusing on Black, Latinoa, and Medicaid-enrolled individuals in Massachusetts who may have had less access to genetic testing and early cancer detection services. This study aims to test whether providing education about genetic testing and multi-cancer early detection MCED testing through online materials alone or combined with a phone call from a trained educator is practical, acceptable, and delivered as planned. Participants will be randomly assigned to receive either only online educational materials or online materials plus a telephone education session from a Pancreatic Cancer Action Network PanCAN educator. After education, participants may choose to have genetic testing using a saliva kit andor MCED testing via blood samples collected at home or a local facility. Positive test results lead to follow-up with specialists at Dana-Farber Cancer Institute, including diagnostic imaging if needed. The study collects data over approximately 6 to 9 months, including surveys and follow-up assessments. Participants complete surveys before and after education, and after testing or declining testing, to measure satisfaction, knowledge, and decision-making. The study tracks completion of genetic and MCED testing, acceptability of education, and adherence to the telephone education content. Safety monitoring includes follow-up for positive MCED results. Participation involves remote activities with some in-person visits only if diagnostic testing is indicated. Enrollment is expected to last about 18 months with a total study completion by March 2029.

CONDITIONS

Brief Title

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

Research Team

T

Tia Kauffman, MPH

J

Jenna Beckwith, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here